Literature DB >> 7854192

Analysis of human immunodeficiency virus type 1 protease activity in eukaryotic and bacterial cells.

A H Kaplan1, M Manchester, L Everitt, R Swanstrom.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7854192     DOI： 10.1016/0076-6879(94)41059-3

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN： 0076-6879            Impact factor:   1.600


× No keyword cloud information.
  7 in total

1.  Activation of the Mason-Pfizer monkey virus protease within immature capsids in vitro.

Authors:  S D Parker; E Hunter
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-27       Impact factor: 11.205

2.  Determinants of the human immunodeficiency virus type 1 p15NC-RNA interaction that affect enhanced cleavage by the viral protease.

Authors:  N Sheng; S C Pettit; R J Tritch; D H Ozturk; M M Rayner; R Swanstrom; S Erickson-Viitanen
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

3.  A genetic screen for the isolation and characterization of site-specific proteases.

Authors:  H J Sices; T M Kristie
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-17       Impact factor: 11.205

4.  Conditional human immunodeficiency virus type 1 protease mutants show no role for the viral protease early in virus replication.

Authors:  A H Kaplan; M Manchester; T Smith; Y L Yang; R Swanstrom
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

5.  Sequence requirements of the HIV-1 protease flap region determined by saturation mutagenesis and kinetic analysis of flap mutants.

Authors:  W Shao; L Everitt; M Manchester; D D Loeb; C A Hutchison; R Swanstrom
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-18       Impact factor: 11.205

6.  The activity of the protease of human immunodeficiency virus type 1 is initiated at the membrane of infected cells before the release of viral proteins and is required for release to occur with maximum efficiency.

Authors:  A H Kaplan; M Manchester; R Swanstrom
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

7.  Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector.

Authors:  I J Caley; M R Betts; D M Irlbeck; N L Davis; R Swanstrom; J A Frelinger; R E Johnston
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.